Gilabert Marine, Audebert Stéphane, Viens Patrice, Borg Jean-Paul, Bertucci François, Gonçalves Anthony
Institut Paoli-calmettes, Centre de recherche en cancérologie de Marseille, U891 Inserm, oncologie médicale, Marseille, France.
Bull Cancer. 2010 Mar;97(3):321-39. doi: 10.1684/bdc.2010.1061.
A major challenge of breast cancer research is the identification of accurate biomarkers that improve screening, early diagnosis, prediction of aggressiveness and prediction of therapeutic response or toxicity as well as the identification of novel molecular therapeutic targets. Following the sequencing of the human genome and pioneer developments of transcriptomics, analysis of the proteome (the repertoire of proteins expressed in a biological samples) was recently introduced as a promising tool in the study of biology of human cancers. In spite of their current limitations, proteomics, either array-based (such as tissue microarrays, antibody arrays or reverse phase protein microarrays) or mass spectrometry-based, make possible to envision major improvements in the molecular knowledge of breast cancer and for the identification of tissue-based or circulating diagnostic and theragnostic biomarkers relevant to this disease. The current techniques applied to clinical samples of breast cancer and the most important results obtained are summarized in this review.
乳腺癌研究的一个主要挑战是识别准确的生物标志物，这些标志物可改善筛查、早期诊断、侵袭性预测、治疗反应或毒性预测，以及识别新的分子治疗靶点。随着人类基因组测序以及转录组学的开创性发展，蛋白质组（生物样品中表达的蛋白质库）分析最近作为一种有前景的工具被引入人类癌症生物学研究。尽管目前存在局限性，但基于阵列（如组织微阵列、抗体阵列或反相蛋白质微阵列）或基于质谱的蛋白质组学，使得在乳腺癌分子知识以及识别与该疾病相关的基于组织或循环的诊断和治疗生物标志物方面取得重大进展成为可能。本综述总结了目前应用于乳腺癌临床样本的技术以及所取得的最重要成果。
